PCSK9 and familial hyperaldosteronism: FH is diagnosed based on the identification of mutations in the genes involved in the hepatic clearance of LDL-C, including LDL receptor (LDLR), apolipoprotein B (APOB) and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) [1,4].